Crash course on Computational Biology for Computer Scientists
... Effective tools are used in short read mapping using BWT and FMI Index can be linear in genome size and match finding with small (<3) number of mismatches is feasible Large number of mismatches works against these methods ...
... Effective tools are used in short read mapping using BWT and FMI Index can be linear in genome size and match finding with small (<3) number of mismatches is feasible Large number of mismatches works against these methods ...
conduction abnormalities in arrhythmogenic right
... found in 5 patients. Only nine patients presented with AV-block I°. The incidence of conduction abnormalities and complete right bundle branch block was only 6 %. Conclusions: The rate of fibrosis of the conduction system as described in the paper of Tabib cannot be confirmed, as the incidence of co ...
... found in 5 patients. Only nine patients presented with AV-block I°. The incidence of conduction abnormalities and complete right bundle branch block was only 6 %. Conclusions: The rate of fibrosis of the conduction system as described in the paper of Tabib cannot be confirmed, as the incidence of co ...
ppt - Bayesian Gene Expression
... • Performance, comparison with CGHMiner • Analyses of CGH-array cancer data sets • Extensions ...
... • Performance, comparison with CGHMiner • Analyses of CGH-array cancer data sets • Extensions ...
ppt - Sol Genomics Network
... - all available full-length tomato genes in GENBANK - TIGR full-length cDNA sequences (redundantly sequenced) - SGN unigene contigs with 5 or more ESTs - redundnacy correction 456 of 8,097 genes found in available genome sequence (5.6%) Correcting for 85% expectation yields 6.6% of target gene space ...
... - all available full-length tomato genes in GENBANK - TIGR full-length cDNA sequences (redundantly sequenced) - SGN unigene contigs with 5 or more ESTs - redundnacy correction 456 of 8,097 genes found in available genome sequence (5.6%) Correcting for 85% expectation yields 6.6% of target gene space ...
Hox Genes - Wyoming Scholars Repository
... multiplying. Of course, this is under the assumption that these Hox genes are the only driving force behind the cancer. In reality this is probably not as simple. Differentiated-expression of Hox genes could also be a factor in numerous other diseases, and given the time and money further research c ...
... multiplying. Of course, this is under the assumption that these Hox genes are the only driving force behind the cancer. In reality this is probably not as simple. Differentiated-expression of Hox genes could also be a factor in numerous other diseases, and given the time and money further research c ...
1 Genome Project-write: A Grand Challenge Using Synthesis, Gene
... transformative, with maximal implications for advancing the biomedical field, deciphering functional consequences of human genome variation and offering related benefits. By focusing on building the 3Gb of human DNA, HGP-write would push current conceptual and tech ...
... transformative, with maximal implications for advancing the biomedical field, deciphering functional consequences of human genome variation and offering related benefits. By focusing on building the 3Gb of human DNA, HGP-write would push current conceptual and tech ...
Leukaemia Section t(7;14)(q35;q32.1) TRB@/TCL1A, inv(14)(q11q32.1) TRA@-TRD@/TCL1A, t(14;14)(q11;q32.1) TRA@- TRD@/TCL1A
... retinoids, nucleosides or fatty acids. In addition to TCL1 and TCL1b the locus contains two additional genes TCL1- neighboring gene (TNG1 and TNG2) encoding proteins of 141 and 110 amino acids. Recently two novel genes have been identified in this region: TML1 and TCL6. Since the TCL1, TCL1b, TML1, ...
... retinoids, nucleosides or fatty acids. In addition to TCL1 and TCL1b the locus contains two additional genes TCL1- neighboring gene (TNG1 and TNG2) encoding proteins of 141 and 110 amino acids. Recently two novel genes have been identified in this region: TML1 and TCL6. Since the TCL1, TCL1b, TML1, ...
Proximal promoter
... (Kim, T. K. et al. Widespread transcription at neuronal activityregulated enhancers. Nature 465, 182–187 (2010).) ...
... (Kim, T. K. et al. Widespread transcription at neuronal activityregulated enhancers. Nature 465, 182–187 (2010).) ...
Gene Section FOXP3 (forkhead box P3) Atlas of Genetics and Cytogenetics
... cancer samples. Out of 223 informative samples, we observed 28 cases (12.6%) with FXOP3 deletion. FOXP3 is likely within the minimal region of deletion in the Xp11 region studied. Although all deletions were heterozygous, the FOXP3 protein was undetectable in 26 out of 28 cases. Thus, it appears tha ...
... cancer samples. Out of 223 informative samples, we observed 28 cases (12.6%) with FXOP3 deletion. FOXP3 is likely within the minimal region of deletion in the Xp11 region studied. Although all deletions were heterozygous, the FOXP3 protein was undetectable in 26 out of 28 cases. Thus, it appears tha ...
Data mining and Knowledge discovery in Biomedical literature
... of each type of DNA in solution is placed onto a speciallyprepared glass microscope slide by an arraying machine. ...
... of each type of DNA in solution is placed onto a speciallyprepared glass microscope slide by an arraying machine. ...
Possible founder effect of rapsyn N88K mutation and identification of
... Possible founder effect of the N88K mutation A haplotype analysis with four extragenic markers located on both sides close to RAPSN was performed to search for an ancestral founder effect. D11S986, D11S1252, D11S4117, and D11S4109 were analysed in all patients, parents when available, and controls. ...
... Possible founder effect of the N88K mutation A haplotype analysis with four extragenic markers located on both sides close to RAPSN was performed to search for an ancestral founder effect. D11S986, D11S1252, D11S4117, and D11S4109 were analysed in all patients, parents when available, and controls. ...
Tulane University Matrix DNA Diagnostics Lab
... FORM 1- Instructions for submission of specimen for DNA testing The patient should be fully informed about the test. Nature of the test/Methodology: The test detects mutations in the gene(s) involved in the synthesis of proteins of connective tissue using Sanger sequencing. Sanger sequencing is high ...
... FORM 1- Instructions for submission of specimen for DNA testing The patient should be fully informed about the test. Nature of the test/Methodology: The test detects mutations in the gene(s) involved in the synthesis of proteins of connective tissue using Sanger sequencing. Sanger sequencing is high ...
Mitosis in Drosophila
... there is a distinct interphase period, enabling transcription to occur. Until this stage, there has been little or no zygotic gene expression and so the components required for the early mitoses must have been provided maternally. One might therefore expect to find a class of maternal-effect lethal ...
... there is a distinct interphase period, enabling transcription to occur. Until this stage, there has been little or no zygotic gene expression and so the components required for the early mitoses must have been provided maternally. One might therefore expect to find a class of maternal-effect lethal ...
Recombinant DNA Technology Lecture Notes
... Cut the plasmid with the same restriction enzyme used to isolate the gene of interest ...
... Cut the plasmid with the same restriction enzyme used to isolate the gene of interest ...
Molecular Genetics Close Notes Booklet
... Mutations come in 3 main varieties: Mutations generally result in a protein that does not function as well or does not function at all. In some rare cases, mutations can provide an advantage and be beneficial. These changes may give that organism a competitive advantage. ...
... Mutations come in 3 main varieties: Mutations generally result in a protein that does not function as well or does not function at all. In some rare cases, mutations can provide an advantage and be beneficial. These changes may give that organism a competitive advantage. ...
Slide 1
... region of the Survivin (BIRC5) gene (Xu et al. 2004). They report that 68% of cancerspecific cell lines (colon, prostate, and breast cancers) contain a C to G transversion at -31 that was not found in any of the normal cell lines tested. BIRC5 is an inhibitor of apoptosis and has been reported as ab ...
... region of the Survivin (BIRC5) gene (Xu et al. 2004). They report that 68% of cancerspecific cell lines (colon, prostate, and breast cancers) contain a C to G transversion at -31 that was not found in any of the normal cell lines tested. BIRC5 is an inhibitor of apoptosis and has been reported as ab ...
Consanguinity and Heterogeneity: Cystic Fibrosis Need Not be Homogeneous in Italy.
... CF children affected with two genetically distinct forms of CF. Under this hypothesis, we calculated the expected frequency of first-cousin marriages in each subset but simply failed to realize that this relative value, which was hypothesized as identical for the two subsets, cannot be doubled. If t ...
... CF children affected with two genetically distinct forms of CF. Under this hypothesis, we calculated the expected frequency of first-cousin marriages in each subset but simply failed to realize that this relative value, which was hypothesized as identical for the two subsets, cannot be doubled. If t ...
From DNA to Proteins
... The conclusion that DNA is the genetic material was not widely accepted at first. It had to be confirmed by other research. In the 1950s, Alfred Hershey and Martha Chase did experiments with viruses and bacteria. Viruses are not cells. They are basically DNA inside a protein coat. To reproduce, a vi ...
... The conclusion that DNA is the genetic material was not widely accepted at first. It had to be confirmed by other research. In the 1950s, Alfred Hershey and Martha Chase did experiments with viruses and bacteria. Viruses are not cells. They are basically DNA inside a protein coat. To reproduce, a vi ...
Who Owns the Human Genome?
... Gilbert does not see what all the fuss is about. "The idea of the company is to be a service to the biotech and pharmaceutical industries and to the research community to answer questions that biologists have in doing research," he told Science. His company, Genome Corporation, "will create a catalo ...
... Gilbert does not see what all the fuss is about. "The idea of the company is to be a service to the biotech and pharmaceutical industries and to the research community to answer questions that biologists have in doing research," he told Science. His company, Genome Corporation, "will create a catalo ...
Hereditary Hemochromatosis Test Information Sheet
... organs including the liver, pancreas, heart, joints, and the brain. Individuals may develop cirrhosis of the liver, liver tumors, diabetes, arthritis, and/or heart disease. Two of the most common defects in the gene for hereditary hemochromatosis (HFE) are the C282Y and H63D mutations. The carrier f ...
... organs including the liver, pancreas, heart, joints, and the brain. Individuals may develop cirrhosis of the liver, liver tumors, diabetes, arthritis, and/or heart disease. Two of the most common defects in the gene for hereditary hemochromatosis (HFE) are the C282Y and H63D mutations. The carrier f ...
Ensembl
... II) High sequence conservation (miRNA) BLAST alignment ‘RNA fold’ applied to make sure sequences can fold (hairpin) ...
... II) High sequence conservation (miRNA) BLAST alignment ‘RNA fold’ applied to make sure sequences can fold (hairpin) ...
Oncogenomics
Oncogenomics is a relatively new sub-field of genomics that applies high throughput technologies to characterize genes associated with cancer. Oncogenomics is synonymous with ""cancer genomics"". Cancer is a genetic disease caused by accumulation of mutations to DNA leading to unrestrained cell proliferation and neoplasm formation. The goal of oncogenomics is to identify new oncogenes or tumor suppressor genes that may provide new insights into cancer diagnosis, predicting clinical outcome of cancers, and new targets for cancer therapies. The success of targeted cancer therapies such as Gleevec, Herceptin, and Avastin raised the hope for oncogenomics to elucidate new targets for cancer treatment.Besides understanding the underlying genetic mechanisms that initiates or drives cancer progression, one of the main goals of oncogenomics is to allow for the development of personalized cancer treatment. Cancer develops due to an accumulation of mutations in DNA. These mutations accumulate randomly, and thus, different DNA mutations and mutation combinations exist between different individuals with the same type of cancer. Thus, identifying and targeting specific mutations which have occurred in an individual patient may lead to increased efficacy of cancer therapy.The completion of the Human Genome Project has greatly facilitated the field of oncogenomics and has increased the abilities of researchers to find cancer causing genes. In addition, the sequencing technologies now available for sequence generation and data analysis have been applied to the study of oncogenomics. With the amount of research conducted on cancer genomes and the accumulation of databases documenting the mutational changes, it has been predicted that the most important cancer-causing mutations, rearrangements, and altered expression levels will be cataloged and well characterized within the next decade.Cancer research may look either on the genomic level at DNA mutations, the epigenetic level at methylation or histone modification changes, the transcription level at altered levels of gene expression, or the protein level at altered levels of protein abundance and function in cancer cells. Oncogenomics focuses on the genomic, epigenomic, and transcript level alterations in cancer.